The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Merck & Co – known as MSD outside the US and Canada – has announced that its respiratory syncytial virus (RSV) preventive ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...